Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Current Leases: 2019-2024

Historic Current Leases for Whitehawk Therapeutics (WHWK) over the last 6 years, with Dec 2024 value amounting to $268,000.

  • Whitehawk Therapeutics' Current Leases fell 38.25% to $268,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $268,000, marking a year-over-year decrease of 38.25%. This contributed to the annual value of $268,000 for FY2024, which is 38.25% down from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' Current Leases is $268,000, which was down 38.25% from $434,000 recorded in FY2023.
  • Whitehawk Therapeutics' 5-year Current Leases high stood at $434,000 for FY2023, and its period low was $125,000 during FY2020.
  • In the last 3 years, Whitehawk Therapeutics' Current Leases had a median value of $394,000 in 2022 and averaged $365,333.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Current Leases soared by 200.76% in 2022, and later tumbled by 38.25% in 2024.
  • Whitehawk Therapeutics' Current Leases (Yearly) stood at $125,000 in 2020, then climbed by 4.80% to $131,000 in 2021, then surged by 200.76% to $394,000 in 2022, then rose by 10.15% to $434,000 in 2023, then tumbled by 38.25% to $268,000 in 2024.